PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]
Merck has broken ground on the €250 million Merck Biotech Development Center, a new biotech development facility in Switzerland at Corsier-sur-Vevey. The new facility will be used for biotech development and manufacturing for clinical studies. Construction on the biotech development facility is likely to be wrapped up next year with full operations to begin by […]
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]
Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up to $576 million, as per the latest pharma acquisition news. Calporta Therapeutics, which was launched in early 2015, is engaged in the development of selective small-molecule agonists to TRPML1. According to COI Pharmaceuticals, TRPML1 is thought to […]
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]
Recarbrio FDA approval : Merck & Co. has secured approval from the US Food and Drug Administration (FDA) for its antibacterial drug product Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of adults having complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Recarbrio is a three-drug combination injection made up of the FDA-approved […]
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono research and development (R&D) facility located in Billerica, Massachusetts. This expansion, which includes the construction of a new building, is set to drive innovations in critical areas like oncology, immuno-oncology, and immunology, helping the company advance its […]
German pharmaceutical giant Merck is set to invest $70 million to expand its EMD Serono research and development (R&D) facility in Billerica, Massachusetts. This major investment will support the company’s efforts in advancing drug discoveries, specifically in oncology, immuno-oncology, and immunology. The expansion, which includes the construction of a new 145,000 square-foot building, will help […]
